Emboliner Embolic Protection System (EPC-03)
Emboline, Inc. · Decision date Sep 8, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision on 2026-09-08 for the Emboliner Embolic Protection System (EPC-03), submitted by Emboline, Inc. of Santa Cruz, California, under 510(k) number K261715. The device falls under classification name Temporary Catheter, Embolic Protection, Transcatheter Intracardiac Procedures, regulation number 870.1251, product code PUM, with a Cardiovascular medical specialty and review panel. The application was received on 05/22/2026.
A SESE decision is a 510(k) clearance, not a premarket approval. The record lists the submission as Traditional, notes it was not reviewed by a third party, identifies it as a combination product, and states that no Predetermined Change Control Plan was authorized. A clinical trial, NCT05684146, is referenced. The page does not describe the device's components, indications, or performance data, and no summary statement is included in the public information, so those details remain unknown here.
The public record does not state the predicate device or the basis for the equivalence determination, and it does not address clinical outcomes. Readers should not infer efficacy, patient-selection criteria, or labeling content from this clearance entry.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 8, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261715
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Emboline, Inc.
- Product code
- PUM
- Decision code
- SESE
- Decision date
- Sep 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Temporary Catheter, Embolic Protection, Transcatheter Intracardiac Procedures.
- Applicant
- Emboline, Inc.
- Product code
- PUM
- FDA device class
- 2
FDA decision timeline
K261715 received
Application receipt date recorded by FDA.
K261715 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Emboline, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Santa Cruz, CA
Sources and methodology
- Original FDA record: K261715
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records